| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378876 | Bioorganic & Medicinal Chemistry Letters | 2006 | 5 Pages |
Abstract
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid and analogs were designed and synthesized as highly potent and selective CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBAs), with demonstrated in vivo efficacy to increase the half-life of exogenous atRA.
Graphical abstract3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid and analogs were designed and synthesized as highly potent and selective CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBAs), with demonstrated efficacy in vivo to increase the half-life of exogenous atRA.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
![3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent](/preview/png/1378876.png "First Page Preview: 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent")
Authors
Mark J. Mulvihill, Julie L.C. Kan, Andrew Cooke, Shripad Bhagwat, Patricia Beck, Mark Bittner, Cara Cesario, David Keane, Viorica Lazarescu, Anthony Nigro, Christy Nillson, Bijoy Panicker, Vanessa Smith, Mary Srebernak, Feng-Lei Sun, Matthew O’Connor,